



HAL
open science

Rapid evaporative ionisation mass spectrometry and chemometrics for high-throughput screening of growth promoters in meat producing animals

Yann Guitton, Gaud Dervilly-Pinel, Renata Jandova, Sara Stead, Zoltan Takats, Bruno Le Bizec

► To cite this version:

Yann Guitton, Gaud Dervilly-Pinel, Renata Jandova, Sara Stead, Zoltan Takats, et al.. Rapid evaporative ionisation mass spectrometry and chemometrics for high-throughput screening of growth promoters in meat producing animals. Food additives & contaminants. Part A. Chemistry, analysis, control, exposure & risk assessment, 2018, 35 (5), pp.900-910. 10.1080/19440049.2017.1421778 . hal-02617785

HAL Id: hal-02617785

<https://hal.inrae.fr/hal-02617785v1>

Submitted on 25 Nov 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Rapid Evaporative Ionization Mass Spectrometry and chemometrics for high-throughput screening of growth promoters in meat producing animals

Yann Guitton^{1#}, Gaud Dervilly-Pinel^{1*#}, Jandova Renata², Sara Stead², Zoltan Takats³, Bruno Le Bizec¹

1 LUNAM Université, Oniris, Laboratoire d'Étude des Résidus et Contaminants dans les Aliments (LABERCA), UMR INRA 1329, Nantes F-44307, France

2 Waters Corporation, Altrincham Road, SK9 4AX Wilmslow, United Kingdom

3 Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, United Kingdom

*corresponding author


gaud.dervilly@oniris-nantes.fr

laberca@oniris-nantes.fr

both first-authors, contributed equally

ABSTRACT: In a proof of concept perspective, Rapid evaporative ionization mass spectrometry (REIMS) was explored for the direct analysis of meat samples from β -agonist treated livestock. In this context, the combination of REIMS with untargeted metabolomics was investigated to identify carcasses from treated animals on the basis of a modification of indirect metabolites profile. The REIMS analysis generated specific lipid profiles which enabled the differentiation of meat samples collected from pigs treated with ractopamine *via* their feeding regime. Furthermore, the strategy was found successful when tested on different muscle types (loin, shoulder and thigh), which further expands its applicability. Classification performances were greater than 95% accurate which fully answers requirements of a screening strategy. This research indicates that REIMS implemented in an untargeted-metabolomics workflow can be considered as a high-throughput and accurate strategy for real-time meat classification in relation to ractopamine (and wider β -agonists) treatment in pig production. This approach may subsequently be implemented as a rapid screening test, at the slaughterhouse or at boarder inspection points, to detect such practice.

Key words: β -agonist, pig, muscle, REIMS, iKnife, metabolomics, biomarkers, ractopamine



31

32

33 Graphical Abstract: REIMS for direct detection of meat samples from ractopamine treated livestock

34

35

36

37 INTRODUCTION

38 β -agonist drugs are synthetic molecules used for therapeutic purposes in human as well as in veterinary medicine
39 for their anti-asthmatic, bronchodilator, tocolytic and cardiotoxic properties. They may also be used for growth
40 promoting purposes in livestock although such practice received extra-attention after outbreak of food poisoning
41 caused by consumption of contaminated bovine tissues in 1990 in Spain (Martinez Navarro 1990): it was the first
42 time that β -agonist residues present in slaughtered cattle were found to have caused acute toxicity in consumers.
43 Later on, similar outbreaks were also reported in France (Pulce et al. 1991), in 1996 in Italy (Brambilla et al. 2000) or
44 2001 in Portugal (Barbosa et al. 2005). Ractopamine in particular is used in animal feed to improve weight gain,
45 carcass leanness and feed efficiency in more than 20 countries, including the United States, Canada, Japan, South
46 Africa and Mexico. During its 2010 meeting, the Joint FAO/WHO Expert Committee on Food Additives (JECFA)
47 established maximum residue limits (MRLs) for ractopamine in muscle ($10 \mu\text{g}\cdot\text{kg}^{-1}$), fat ($10 \mu\text{g}\cdot\text{kg}^{-1}$), liver ($40 \mu\text{g}\cdot\text{kg}^{-1}$)
48 and kidney ($90 \mu\text{g}\cdot\text{kg}^{-1}$) in pig and cattle (JECFA 2010). On 6 July 2012, the international reference standard *Codex*
49 *Alimentarius* Commission narrowly approved the adoption of the MRLs although setting any limit was a controversial
50 move. However, recent research confirmed that using ractopamine can affect the heart, thyroid, urethra and prostate
51 (Catalano et al. 2012). Therefore, any proposals to ban ractopamine in food-producing animals is still with
52 controversy. Countries, such as those of the European Union and China, have not approved the usage of any β -
53 agonist, including ractopamine, as growth promoters (Council Directive 96/22/EC 1996; MOA. 2002; EFSA. 2009).
54 However, and despite the ban, its illegal use in food producing animals is regularly suspected in Europe; a particular
55 attention is given at Border Inspection Posts (BIP) to any edible tissues imported from third countries. Consequently,
56 analytical strategies have been developed to comply with the regulation and ensure control of such practices (Le
57 Bizec et al. 2009). Confirmatory strategies targeting β -agonists residues in various relevant biological matrices (urine,
58 serum, tissues, retina, hair) enable long term detection of forbidden practices. However, the extent to which such
59 practice occurs is still difficult to evaluate since screening is an enormous challenge. To meet the requirement for
60 screening illicit practices, "Omics" strategies, based on the observation of physiological perturbations, are promising
61 approaches to tackle drug misuse in breeding animals (Riedmaier et al. 2009; Pinel et al. 2010; Nebbia et al. 2011;
62 Dervilly-Pinel G. et al. 2012; Gallart Ayala et al. 2015). Particularly, metabolomics based on mass spectrometry
63 analytical platforms have proven their efficiency in highlighting candidate biomarkers of anabolic treatments in
64 livestock (Dervilly-Pinel G. et al. 2011; Jacob C et al. 2014; Jacob CC et al. 2014; Jacob C et al. 2015; Kouassi
65 Nzoughet J et al. 2015; Kouassi Nzoughet JJ et al. 2015) and sport animals (Boyard-Kieken et al. 2011; Kieken et al.
66 2011). During the past few years, several metabolomics studies have been reported for the control of β -agonists in
67 livestock. Courant et al. (Courant et al. 2009) developed an untargeted metabolomics approach based on High

68 Performance Liquid Chromatography coupled to High-Resolution Mass Spectrometry (HPLC-HRMS) and made it
69 possible to highlight metabolic modifications in calves' urine directly to a clenbuterol administration. Later on, Dervilly-
70 Pinel et al. (Dervilly-Pinel Gaud et al. 2015) proposed a validated LC-HRMS (Orbitrap) metabolomics strategy
71 enabling implementing a robust statistical model to screen for calves which have been treated with β -agonist
72 compounds. At the same time, Wu et al. (Wu et al. 2015) outlined a metabolomics based strategy for detection of the
73 use of "cocktails" composed of mixtures of sub-therapeutic doses of the individual β -agonists (clenbuterol,
74 salbutamol, and ractopamine) *via* pig urine profiling through LC-HRMS (Q-TOF). Until now however, most studies
75 have been focusing on clenbuterol as a model of β -agonists for metabolomics investigation. Peng et al. (Peng et al.
76 2017) recently reported a number of serum candidate biomarkers specifically associated to ractopamine
77 administration in pig production also based on LC-HRMS metabolomics.

78 Due to the non-invasive nature of the sample collection for live animals, urine of, e.g. bovine and pig, has primarily
79 been the matrix of choice in these metabolomics studies (Courant et al. 2009; Jacob CC et al. 2013; Dervilly-Pinel
80 Gaud et al. 2015; Wu et al. 2015), while later on, serum or plasma has also been efficiently investigated (Peng et al.
81 2017). Conversely, sampling the edible tissue (muscle, liver, kidney...) offers the advantage over biofluid analysis of
82 allowing direct control of the food commodity. This is of prime importance for instance in the case of importation at
83 the border. In this context, a single study by Li et al. (2016) reported a successful porcine muscle and fatty tissue
84 metabolomics investigation after clenbuterol treatment using gas chromatography-mass spectrometry (GC-MS). The
85 promising outcome fully justifies considering edible tissues as matrices of interest to highlight β -agonist administration
86 food producing livestock.

87 In the current international context, developing an efficient and high-throughput metabolomics workflow directly
88 applicable for the sampling of edible meat and enabling immediate prediction of its (β -agonist) status would be
89 considered a breakthrough in the field to reveal biological effects in drug treated animals and efficiently tackle illegal
90 practice.

91 Rapid Evaporative Ionization Mass Spectrometry (REIMS) is a new emerging technique enabling direct ionization
92 from the sample combined with mass spectrometric analysis (St John et al. 2016). REIMS determines the structural
93 lipid profile of tissues by the on-line analysis of electrocautery smoke and uses this information for the rapid
94 characterization of dissected tissues. The analysis takes only a few minutes and guarantees point-of-control analysis.
95 Originally it was intended for *in vivo* identification of tissues during surgical interventions (Balog et al. 2013); it was
96 recently reported in food applications, in particular, its feasibility was successfully demonstrated for the identification
97 of the species of origin (Balog et al. 2016) or quality (Verplanken et al. 2017) of meat products. A known consequence
98 of the administration of β -agonist compounds to livestock is the development of leaner muscle tissue; therefore, a
99 perturbation in the lipid profiles of tissue from animals treated with β -agonist compounds compared to the control
100 population is hypothesized. In a proof of concept perspective, the present research intended to explore the use of

101 REIMS to develop a predictive model for the accurate, real-time determination of muscle samples originating from
102 ractopamine treated pigs.

103

104

105 **1. EXPERIMENTAL SECTION**

106 1.1 Experimental design

107 The animal study was approved by the national Ethical Committee (n°6) under agreement 2015092516084715 /
108 APAFIS 1914 (CRIP-2015-054). Ten four months' old female pigs (Axior Porc Charcutier) (Terrena, Ancenis, France)
109 weighing 40 kg were randomly divided into control (n = 5 animals) and treated (n = 5 animals) groups. Animals were
110 allowed a three-day acclimatization period, following which each animal received 1.8 kg feed/day. Pigs from the
111 treatment group received feed containing ractopamine hydrochloride (Sigma Aldrich), at a dose of 10 mg/kg feed, on
112 a daily basis over a 29 day period. The 10 ppm daily dose was selected as corresponding to classical doses used in
113 finishing pigs, where that approval for use exists. Three different muscle type (Shoulder (E), Loin (F) and Thigh (J))
114 samples were collected from each animal carcass at the end of the experiment, frozen and then stored at -20°C for
115 subsequent REIMS analysis. For ractopamine residue confirmation, muscles were freeze-dried and grounded before
116 analysis.

117 In addition, three samples of pork muscle were purchased at the local supermarket and used as part of the validation
118 study.

119

120 1.2 Methods

121 REIMS fingerprinting: After thawing, muscles were cut in 1 cm x 4 cm sections and submitted to REIMS analysis as
122 follows. The iKnife hand-held sampling device (Waters, Milford, MA USA) was used to apply a localized high
123 frequency electric current to the surface of each sample, which instantly vaporizes molecules from the latter. It
124 consisted of a monopolar cutting device with a shortened knife blade approximately 6 mm long and was applied in
125 auto-cut mode in combination with a diathermy electrosurgical generator (Erbe VIO 50 C) (Erbe, Tuebingen,
126 Germany) at a power of 25 W. Sampling was carried out for 3 to 5 seconds and for each sample, three technical
127 replicates were analyzed, thus taking into account repeatability of the analysis. Mass spectrometric analysis was
128 performed using a Synapt G2 Si instrument equipped with prototype REIMS source comprising a helical coiled ribbon
129 collision surface heated by a constant current power supply set to 4.5 A (Kanthal D 1.0×0.1 mm) (Waters Corporation,
130 MA USA). All analysis was performed in REIMS TOF MS sensitivity mode with continuum data acquisition.
131 Isopropanol was infused directly into the REIMS source at a constant flow rate of 200 µl min⁻¹ to promote the
132 ionization of lipid (fatty acid and phospholipid) species and maintain source cleanliness. The mass resolution was
133 approximately 20 000 FWHM over the mass range of interest. The declustering voltage (labelled cone voltage) is the

134 DC potential applied between the last electrode of the first stepwave and the differential pumping aperture between
135 the first stepwave vacuum region and the second vacuum region; this was set at difference of 100 V. Mass
136 spectrometric analysis was performed in negative ionization mode over a mass range of 50–1200 m/z with an
137 integration (scan) time of 1 s/scan. Prior to use, the instrument was calibrated using sodium formate in isopropanol
138 and was infused via the matrix inlet on the REIMS source. For quality control purposes, the endogenous matrix ion
139 PE (34:1) [M-NH4]⁻ C₃₉H₇₆NO₈P with m/z 699.497 was used as an internal lock-mass compound to maintain mass
140 accuracy. Furthermore, replicate burns of a QC sample (porcine liver) were collected after every 10 porcine muscle
141 samples. The intensity of the base peak ion at m/z 699.497 was recorded and plotted for quality control monitoring.
142 The iKnife blade was cleaned using methanol after every 15 measurements and the three-meter-long transfer tubing
143 and venturi air pump was cleaned in an ultrasonic bath using methanol at the end of each day. A reference sample
144 of porcine liver was analysed after every 10 samples measured. The ion intensity of the base peak at m/z 699.49
145 obtained from the reference sample spectra was plotted in a control chart so that any deviations in instrument
146 performance would be quickly identified.

147

148 An untargeted mass spectrometric analysis was performed to discriminate between muscle samples collected from
149 control and treated animals. The ten loin muscles (MF) were analyzed in triplicate (as a minimum) on each of three
150 separate days and using two different REIMS sources (operated on the same MS instrument), in order to take into
151 account technical variation and intra-laboratory reproducibility. This step thus generated a total of 106 mass spectra
152 (50 spectra for the control and 56 for the treated class), that were used to define the database and consequently train
153 the model. In addition, samples from each of the ten study animals were collected from the shoulder (ME) and thigh
154 (MJ) muscles that were also analyzed in triplicate on the first analysis day and used as an independent validation set
155 to the model created from the loin samples.

156

157 Ractopamine analysis: Muscles have been analysed for ractopamine residue according to a validated and ISO17025
158 accredited method (Antignac et al. 2002). Starting with 20 g of freeze-dried muscle the method briefly consists in a
159 deconjugation step with *Helix pomatia* for 15h at 52 °C, followed by a mixed mode SPE purification step (CSDAU,
160 SDS, Peypin, France). Separation of the compounds was performed on a C18 column (50 x 2,1 mm, 3 µm (Uptisphere
161 3HDO – Interchim, Montluçon, France)) and MS identification using a triple quadrupole (Waters Xevo T-QS) in the
162 SRM acquisition mode. Criteria of Decision 2002/657/EC (Council Decision 2002/657/EC 2002) were applied.
163 Quantification was performed using isotope dilution principle using ²H₉-méthylcimaterol, as the labelled internal
164 standard.

165

166 1.3 Chemometric data analysis and recognition

167 Multi-variate statistical software package LiveID™ (Waters Corporation, Wilmslow, UK) was used as a model builder
168 and recognition tool. In order to generate models from the untargeted profiling REIMS ToF MS data acquired in
169 MassLynx v. 4.1 (Waters Corporation, Wilmslow, UK) the following data treatment steps were performed; lock-mass
170 correction applied using the endogenous matrix ion at m/z 699.497; all spectra contained within each “burn event”
171 termed the region of interest (ROI) were combined to form a single continuum spectrum; Adaptive Background
172 Subtraction (ABS) algorithm was applied to reduce the chemical background in the combined spectra; data re-
173 sampling (binning to 0.1 Da) was performed to reduce the data dimensionality; the resulting spectrum was normalised
174 using the TIC For principal component analysis (PCA), the data was centered using the mean value of the entire data
175 set. For linear discriminate analysis (LDA), the data was centered using the mean values of each model class. In
176 either type, the mean for each m/z bin is subtracted from the values of that bin. Other than normalisation and
177 centering, no additional manipulation was performed (for example, scaling).

178

179 Following data pre-treatment steps, a PCA/LDA model was calculated. Firstly, an unsupervised PCA (Singular Value
180 Decomposition algorithm) transform is applied to the spectral data calculating the scores and loadings; a supervised
181 LDA transform is then applied to the scores calculated by the PCA transform. LDA is a transform that maximizes the
182 inter-class variance, while minimizing the intra-class variance, resulting in a projection where examples from the
183 same class are projected close to each other and, at the same time, the class centres (means) are as far apart as
184 possible. Although it is not a true regularization technique, PCA-LDA is found to reduce the chance of over-fitting that
185 may occur with a pure LDA model.

186

187 During the recognition step, the model transforms spectra acquired from test samples into the associated model-
188 space, after which, a classifier decides to which class (if any) the spectra belongs. The model classifier uses a
189 multivariate normal distribution (MVN) for each model class. During the model building phase, these distributions are
190 constructed by transforming the training spectra to generate scores for the n principal components/linear
191 discriminants selected for the model. The number of dimensions in the MVNs is also equal to n . The MVNs produce
192 a likelihood measure for each class, and Bayes' rule was then applied to derive posterior probabilities.

193

194 *In silico* 5-fold stratified validation was performed to determine the predictive accuracy of the ractopamine screening
195 model. The model-building data set was divided in five partitions (5-fold), each of which contains a representative
196 proportion of each class within it (stratified). Four partitions (80%) of data set are used to build a model under the
197 same conditions as the original model. This model is used to predict the classifications of the one partition (20%) of
198 the training set that was left out. The cycle was repeated iteratively 5 times and each partition was predicted once by
199 a model trained from the other four. The output of the validation details the total number of correct and incorrect

200 classifications, as well as the number of outliers. Outliers were calculated according to the Mahalanobis distance
201 (Mahalanobis, 1936) to the nearest class center. If this distance is greater than the outlier threshold, the sample is
202 considered an outlier. Following iterations of model optimization, an independent validation step was performed using
203 the ME and MJ sample series not included in the training set.

204

205 For independent comparison purposes with LiveID™ outputs, additional and complementary statistical analyses
206 (OPLS-DA, HC) were performed using MetaboAnalyst 3.0 (Xia et al. 2015; Xia and Wishart 2016), Progenesis Q1
207 (Non Linear Dynamics, Waters Corporation, Newcastle, UK), EZInfo and SIMCA-P (Umetrics Sartorius Stedim
208 Biotech, Sweden).

209

210 The different steps of the workflow are illustrated on the flow diagram presented in Figure S1. Resources and time
211 effort are further indicated.

212

213 **2. RESULTS AND DISCUSSION**

214 2.1 Ractopamine residue analysis

215 Muscle samples collected from control pigs were all shown to be free of ractopamine (and associated metabolites),
216 while muscle tissue collected from treated animals was found to be incurred with ractopamine residues. The
217 measured concentrations in the treated population were found to be in the range of 1-2 $\mu\text{g}\cdot\text{kg}^{-1}$ (ppb), in the three
218 muscle types collected, which confirmed the homogeneous distribution of the drug residue throughout the skeletal
219 muscle as a result of administration of ractopamine *via* feed.

220

221 2.2 REIMS - Database training and challenge

222 The ten loin muscles (coded MF), five from the control and five from the treated populations were analyzed using
223 REIMS in negative ionization mode as a minimum of triplicates on three different days. Within each day, the ten
224 samples were randomized. The mass spectra generated were processed and analyzed with the objective of
225 investigating differences in the metabolic feature profiles between the two populations, control and treated pigs. Data
226 processing enabled feature alignment resulting in 1931 detected deisotoped ions in the range 50-1200 m/z . The
227 spectra were binned at 0.1 Da and the region between 600-1000 m/z was used to generate a multi-variate model
228 with ten PCA dimensions (for data reduction) followed by one LDA dimension for binary classification. During the
229 model optimization phase, ten PCA dimensions were shown to provide the optimum predictive accuracy as
230 determined *via* the % correctness score generated using *in silico* stratified 5-fold validation following iterative rounds
231 of model training using between 2 and 30 PCA components. The % variance explained by each PCA dimension was

232 calculated, and greater than 95% of the total variance was shown to be explained with first 10 components. An outlier
233 threshold of three Standard Deviations was applied. As illustrated, in Figure 1 the model enabled discrimination of
234 the mass spectral profiles corresponding to the muscle samples from either control or treated animals. The predictive
235 classification accuracy was calculated as 99.2% *via* stratified 5-fold *in silico* validation which presented only one
236 “false suspicious” sample out of 106 analyses. Clear discrimination between treated and control populations was also
237 observed using both an alternative data analysis algorithm (OPLS-DA) and software (MetaboAnalyst 3.0) (Figure
238 S12) ensuring confident separation of the two classes and confirming the ability of the studied ionization strategy to
239 provide specific fingerprints of muscle samples in relation with growth promoting practice during the breeding period.
240 Some scatter in the data was observed between the different analysis days, however, this did not affect the grouping
241 in the multivariate analysis scores plot.

242

243 The model was subsequently challenged using 21 different samples collected from the same animal study (11 control
244 and 10 treated) not included in the model training set originating from different muscle locations (MJ series thigh
245 (n=9), MF series loin (n=2) and ME series shoulder (n=10)) in triplicate using the real-time recognizer functionality
246 (Figure S3). The overall outcome was determined from the mean of the three replicates (Table 1). Individual results
247 having a % confidence matching factor of less than 80% were excluded from the overall outcome. On the basis of
248 the independent validation, all muscle samples except one (an MJ series treated sample) were correctly classified
249 leading to an overall correct assignment rate of $\geq 95\%$. Based on these findings a 0% false positive rate and a 10%
250 false negative rate was estimated. Such preliminary performances are very encouraging, especially considering the
251 relatively low number of samples involved and that different muscles types have been considered, in an experimental
252 design corresponding to expected practices of use in finishing animals, where no withdrawal period is applied. Further
253 improvements to the model performance are therefore easily envisaged whereby the model training set is expanded
254 to include representative samples from the other muscle locations due to the observed variation in physiological lipid
255 depositions in different muscle location. However, the preliminary performance shows relevance with the screening
256 requirements as expressed in Dec 2002/657/EC (Council Decision 2002/657/EC 2002) where a maximum of 5%
257 false negative is considered acceptable.

258

259 Further, the applicability of the strategy on fresh pork meat samples purchased at local supermarkets was evaluated.
260 Three different meat samples were profiled using the REIMS and corresponding fingerprints were automatically
261 processed for recognition against the established model. The samples were analyzed a minimum of ten times each
262 and were recognized in 100% cases as control pork meat (Figure S4), in accordance with what was expected for
263 meat samples collected in the EU.

264

265 2.3 Preliminary pathway analysis

266 Although the identification of lipid species affected by ractopamine was not the objective of the current work,
267 preliminary hypothesis could be drawn, which will require future appropriate MS/MS investigation. The loading S-plot
268 associated with PCA/LDA (Figure 2a) and OPLS-DA (Figure 2b) shows significant features involved in class
269 separation. Closer investigation shows that members of the diacylglycerophosphoethanolamine (PE),
270 phosphatidylinositol (PI), sphingomyelin (SM) and free fatty acid classes as present in the extremity region are
271 significantly involved in the differentiation of control and ractopamine treated pig populations. Complementary
272 investigation of interesting features was also performed through hierarchical clustering analysis which confirmed
273 relevance of previously highlighted species (Figure 3). The main affected lipids are detailed in Table 2 and Figure S5
274 (putative identification). The compounds highlighted as lipid species whose profiles would be significantly affected by
275 ractopamine were further selected for pathway analysis using MetabolAnalyst 3.0 software and Lipid Maps (Fahy et
276 al. 2007; Fahy et al. 2009). It could, thus, be hypothesized that glycerophospholipid metabolism was implicated as
277 the most significant involved pathway. REIMS, which specifically allows detection of phospholipids, therefore appears
278 as a technique of choice in this context. Further investigations down to the acyl-composition is now required to
279 conclude on lipids identity and name concrete pathways.

280

281 The link between ractopamine and lipid metabolism has been investigated decades ago in farm animals (Dunshea
282 FR. 1993). A reduction in the deposition of adipose tissue in the carcass of pigs fed the diets containing ractopamine
283 has been reported by many authors (Uttaro et al. 1993; See et al. 2004; Mimbs et al. 2005). Such an effect is
284 hypothesised to occur through either or both two metabolic pathways: reduction in lipogenesis and increase in
285 lipolysis. In the 1980s, a number of scientist believed that β -agonists had the property (in various animals such as
286 lamb, swine or steers) of stimulating the lipolysis in adipose tissue, catalysed by the hormone-sensitive lipase and
287 releasing free fatty acids into the blood stream (Baker et al. 1984; Ricks et al. 1984; Jones et al. 1985). These authors,
288 however, who worked with the determination of lipolysis in the pigs through the quantification of serum NEFAs did
289 not find any increase in these elements (Dunshea FR. and King 1994, 1995), thereby indicating that lipolysis might
290 not be the preponderant factor in the reduction in the amount of adipose tissue deposited in the carcass of pigs. The
291 same authors also suggested that ractopamine at doses of 0 and 20 ppm did not stimulate fat mobilization or lipolysis
292 in the pigs or, if it occurred, the effect disappeared after three days. Later (Dunshea FR. et al. 1998) they reported
293 that ractopamine promotes protein deposition with little effect on fat deposition in the pig. In particular, they
294 investigated whether the lack of effect on fat deposition was due to a lack of effect of ractopamine on lipogenesis.
295 They demonstrated that dietary ractopamine increased average daily gain ($P < 0.050$) and glucose turnover by 24%,
296 presumably to support the increased skeletal muscle protein deposition that occurs during dietary ractopamine
297 treatment. They could not demonstrate any effect of dietary ractopamine on the rate of lipogenesis in adipose tissue.
298 More recently and considering the lack of consensus in the literature regarding the mechanisms responsible for the

299 effects of ractopamine on the metabolism of lipids (da Silva Ferreira et al. 2013) reviewed *in vivo* mechanism of action
300 through which ractopamine reduces the amount of adipose tissue in carcass of animals fed diets supplemented with
301 this drug. The review analysis explained that in the pigs, the use of ractopamine reduced lipid deposition in the
302 carcass due to a greater inhibition of lipogenesis than an increase in lipolysis.

303 Our results suggest global alteration of lipid profile with mainly higher amounts of some
304 diacylglycerophosphoethanolamine (PE) and phosphatidylinositol (PI) in muscle tissues collected on ractopamine
305 fed pigs. Such observations, however, could not be related to any conclusion on lipogenesis or lipolysis as reported
306 by previous studies above which were performed in serum.

307

308 **3. CONCLUSION**

309 Recent technological advances using innovative mass spectrometry technologies combined with omics strategies
310 are now well suited to address the issue associated to rapid classification of food samples to guarantee chemical
311 food safety to the consumers (Balog et al. 2016). In this context, the REIMS method has been optimized for real-time
312 analysis of pig muscle tissue, and the results suggest spectral analysis is accurate and rapid for determination of the
313 status of the animals regarding exposure to ractopamine during breeding.

314 Further work will establish complete scope and robustness of the screening strategy. In particular, the generality of
315 the approach toward different drugs in this action class will be investigated. In parallel, the false negative rate will be
316 established considering samples from populations under different regimes of expected use.

317 Such emerging strategies are efficient ways to highlight candidate biomarkers of such practices in livestock and are
318 considered by the community as promising tools for ensuring safer food to the consumer in a more efficient way.
319 Furthermore, the LiveID™ software empowers the strategy as it enables real-time classification of unknown samples,
320 through comparison against a trained database. Such workflow can be considered an *in situ* control platform to be
321 implemented at the slaughterhouse or inspection points at the border. A range of food quality applications may also
322 easily be foreseen, whenever high-throughput characterization is a pre-requisite.

323

324

325

326

327

References

328 Antignac J-P, Marchand P, Le Bizec B, André F. 2002. Identification of ractopamine residues in tissue
329 and urine samples at ultra-trace level using liquid chromatography-positive electrospray tandem
330 mass spectrometry. *Journal of Chromatography B*. 774:59-66.
331 Baker P, Dalrymple R, Ingle D, Ricks C. 1984. Use of a β -adrenergic agonist to alter muscle and
332 fat deposition in lambs. *J Anim Sci* 59:1256-1261.

333 Balog J, Perenyi D, Guallar-Hoyas C, Egri A, Pringle SD, Stead S, Chevallier OP, Elliott CT, Takats Z.
334 2016. Instantaneous Identification of the Species of Origin for Meat Products by Rapid Evaporative
335 Ionization Mass Spectrometry. *Journal of agricultural and food chemistry*. Eng.

336 Balog J, Sasi-Szabo L, Kinross J, Lewis MR, Muirhead LJ, Veselkov K. 2013. Intraoperative tissue
337 identification using rapid evaporative ionization mass spectrometry. *Sci Transl Med*. 5.

338 Barbosa J, Cruz C, Martins J. 2005. Food poisoning by clenbuterol in Portugal. . *Food Addit Contam Part*
339 *A Chem Anal Control Expo Risk Assess*. 22:563-566.

340 Boyard-Kieken F, Dervilly-Pinel G, Garcia P, Paris AC, Popot MA, le Bizec B, Bonnaire Y. 2011.
341 Comparison of different liquid chromatography stationary phases in LC-HRMS metabolomics for
342 the detection of recombinant growth hormone doping control. *Journal of separation science*.
343 34(24):3493-3501. eng.

344 Brambilla G, Cenci T, Franconi F, Galarini R, Macri A, Rondoni F, Strozzi M, Loizzo A. 2000. Clinical
345 and pharmacological profile in a clenbuterol epidemic poisoning of contaminated beef meat in italy.
346 *Toxicol Let* 114:47-53.

347 Catalano D, Odore R, Amedeo S, Bellino C, Biasibetti E, Miniscalco B. 2012. Physiopathological changes
348 related to the use of ractopamine in swine: clinical and pathological investigations. *Livestock*
349 *Science*. 144:74-81.

350 Council Decision 2002/657/EC. 2002. Council Decision 2002/657/EC implementing Council Directive
351 96/23/EC concerning the performance of analytical methods and the interpretation of results, . *Off*
352 *J Eur Union*.

353 Council Directive 96/22/EC. 1996. Council Directive 96/22/EC of 29 April 1996 concerning the
354 prohibition on the use in stockfarming of certain substances having a hormonal or thyrostatic action
355 and of beta-agonists, and repealing Directives 81/602/EEC, 88/146/EEC and 88/299/EEC.

356 Courant F, Pinel G, Bichon E, Monteau F, Antignac JP, Le Bizec B. 2009. Development of a metabolomic
357 approach based on liquid chromatography-high resolution mass spectrometry to screen for
358 clenbuterol abuse in calves. *Analyst*. 134(8):1637-1646. eng.

359 da Silva Ferreira MS, Pospissil Garbossa CA, Oberlender G, Pereira LJ, Zangeronimo MG, de Sousa
360 RV, de Souza Cantarelli V. 2013. Effect of Ractopamine on Lipid Metabolism in vivo - a
361 Systematic Review. *Brazilian Archives of Biology and Technology* 56:35-43.

362 Dervilly-Pinel G, Chereau S, Cesbron N, Monteau F, Le Bizec B. 2015. LC-HRMS based metabolomics
363 screening model to detect various β -agonists treatments in bovines. *Metabolomics*. 11:403-411.

364 Dervilly-Pinel G, Courant F, Chereau S, Royer A, Boyard-Kieken F, Antignac J, Le Bizec B. 2012.
365 Metabolomics in food analysis: application to the control of forbidden substances. *Drug testing and*
366 *analysis*. 4:10.

367 Dervilly-Pinel G, Weigel S, Lommen A, Chereau S, Rambaud L, Essers M, Antignac JP, Nielen MW, Le
368 Bizec B. 2011. Assessment of two complementary liquid chromatography coupled to high
369 resolution mass spectrometry metabolomics strategies for the screening of anabolic steroid
370 treatment in calves [Research Support, Non-U.S. Gov't]. *Analytica chimica acta*. 700(1-2):144-154.
371 eng.

372 Dunshea F. 1993. Effect of metabolism modifiers on lipid metabolism in the pig. *J Anim Sci* 71:1966-
373 1977.

374 Dunshea F, King R. 1994. Temporal response of plasma metabolites to ractopamine treatment in the
375 growing pig. *Aust J Agric Res* 45:1683-1692.

376 Dunshea F, King R. 1995. Responses to homeostatic signals in ractopamine-treated pigs. *Br J Nutr*.
377 73:809-818.

378 Dunshea F, Leur B, Tilbrook A, King R. 1998. Ractopamine increases glucose turnover without affecting
379 lipogenesis in the pig. *Aust J Agric Res* 49:1147-1152.

380 EFSA. 2009. Scientific Opinion of the Panel on Additives and Products or Substances used in Animal
381 Feed (FEEDAP) on a request from the European Commission on the safety evaluation of
382 ractopamine. *The EFSA Journal*. 1041(1-52).

383 Fahy E, Subramaniam S, Murphy R, Nishijima M, Raetz C, Shimizu T, Spener F, van Meer G, Wakelam
384 M, Dennis E. 2009. Update of the LIPID MAPS comprehensive classification system for lipids. .
385 Journal of Lipid Research. 50:9-14.

386 Fahy E, Sud M, Cotter D, Subramaniam S. 2007. LIPID MAPS online tools for lipid research. . Nucleic
387 Acids Research. 35:6-12.

388 Gallart Ayala H, Chéreau S, Dervilly-Pinel G, Le Bizec B. 2015. Potential of mass spectrometry
389 metabolomics for chemical food safety. Bioanalysis Review. 7(1):133-146.

390 Jacob C, Dervilly-Pinel G, Biancotto G, Monteau F, Le Bizec B. 2015. Global urine fingerprinting by
391 LC-ESI(+)-HRMS for better characterization of metabolic pathway disruption upon anabolic
392 practices in bovine. Metabolomics. 11:184-197.

393 Jacob CC, Dervilly-Pinel G, Biancotto G, Le Bizec B. 2014. Evaluation of specific gravity as
394 normalization strategy for cattle urinary metabolome analysis. Metabolomics. 10:627–637.

395 JECFA 2010. Evaluation of data on ractopamine residues in pig tissues. FAO JECFA Monographs 9
396 (meeting 2010).

397 Jones R, Easter R, McKeith R. 1985. Effect of the β - adrenergic cimaterol (CL263.780) on the
398 growth and carcass characteristics of finishing swine. . J Anim Sci 61:905-913.

399 Kieken F, Pinel G, Antignac J, Garcia P, Popot M, Grall M, Mercadier V, Toutain P, Bonnaire Y, Le
400 Bizec B. 2011. Development and application of a metabolomic approach based on liquid
401 chromatography-high resolution mass spectrometry to reveal an illegal administration of
402 recombinant equine growth hormone in horse from urinary and plasmatic biological signatures.
403 Metabolomics 7:9.

404 Kouassi Nzoughet J, Gallart-Ayala H, Dervilly-Pinel G, Biancotto G, Le Bizec B. 2015. Original
405 combination of Hydrophilic Interaction (HILIC) and Reverse Phase (RPLC) High Resolution LC-
406 MS for characterizing lipids profile disruption in serum of anabolic implanted bovines.
407 Metabolomics. 11(6):1884-1895.

408 Kouassi Nzoughet JJ, Dervilly-Pinel G, Chéreau S, Biancotto G, Monteau F, Elliott CT, Le Bizec B. 2015.
409 First insights into serum metabolomics of trenbolone/estradiol implanted bovines; screening model
410 to predict hormone-treated and control animals' status. Metabolomics.

411 Le Bizec B, Pinel G, Antignac JP. 2009. Options for veterinary drug analysis using mass spectrometry
412 [Review]. Journal of chromatography A. 1216(46):8016-8034. eng.

413 Martinez Navarro J. 1990. Food poisoning related to consumption of illicit b2-agonist in liver.
414 Lancet.336-1311.

415 Mimbs K, Pringle T, Azain M, Meers S, Armstrong T. 2005. Effects of ractopamine on performance
416 and composition of pigs phenotypically sorted into fat and lean groups. . J Anim Sci 83(1361-
417 69).

418 MOA. 2002. List of Banned Veterinary Drugs and Other Compounds in Food-Producing Animals.
419 Ministry of Agriculture of China 235th Bulletin.

420 Nebbia C, Urbani A, Carletti M, Gardini G, Balbo A, Bertarelli D, Girolami F. 2011. Novel strategies for
421 tracing the exposure of meat cattle to illegal growth-promoters [Review]. Vet J. 189(1):34-42. eng.

422 Peng T, Royer A-L, Guitton Y, Le Bizec B, Dervilly-Pinel G. 2017. Serum-based metabolomics
423 characterization of pigs treated with ractopamine. Metabolomics.

424 Pinel G, Weigel S, Antignac JP, Mooney MH, Elliott C, Nielen MWF, Le Bizec B. 2010. Targeted and
425 untargeted profiling of biological fluids to screen for anabolic practices in cattle. TrAC Trends in
426 Analytical Chemistry. 29(11):1269-1280.

427 Pulce C, Lamaison D, Keck G, Bostvironnois C, Nicolas J, Descotes J. 1991. Collective human food
428 poisonings by clenbuterol residues in veal liver. Vet Hum Toxicol 33(5):480-481.

429 Ricks C, Dalrymple R, Baker P, Ingle D. 1984. Use of β -agonist to alter fat and muscle deposition in
430 steers. . J Anim Sci. 59:1247-1255.

431 Riedmaier I, Becker C, Pfaffl MW, Meyer HH. 2009. The use of omic technologies for biomarker
432 development to trace functions of anabolic agents [Review]. Journal of chromatography A.
433 1216(46):8192-8199. eng.

- 434 See M, Armstrong T, Weldon W. 2004. Effect of a ractopamine feeding program on growth performance
435 and carcass composition in finishing pigs. . J Anim Sci 82:2474-2480.
- 436 St John ER, Rossi M, Pruski P, Darzi A, Takats Z. 2016. Intraoperative tissue identification by mass
437 spectrometric technologies Trends in Analytical Chemistry. 85:2-9.
- 438 Uttaro B, Ball R, Dick P, Rae W, Vessie G, Jeremiah L. 1993. Effect of ractopamine and sex on
439 growth, carcass characteristics, processing yield, and meat quality characteristics of crossbred
440 swine. J Anim Sci 71:2439-2449.
- 441 Verplanken K, Stead S, Jandova R, Poucke C, Claereboudt J, Bussche J, Saeger S, Takats Z, Wauters J,
442 Vanhaecke L. 2017. Rapid evaporative ionization mass spectrometry for high-throughput screening
443 in food analysis: The case of boar taint. Talanta. 169:30-36.
- 444 Wu YP, Bi YF, Bingga GL, Li XW, S.X. Z, Li JC. 2015. Metabolomic analysis of swine urine treated
445 with β 2-agonists by ultra-high performance liquid chromatography-quadrupole time-of-flight mass
446 spectrometry. Journal of Chromatography A. 1400(74-81).
- 447 Xia J, Sinelnikov I, Han B, Wishart DS. 2015. MetaboAnalyst 3.0 - making metabolomics more
448 meaningful Nucl Acids Res. 43:251-257.
- 449 Xia J, Wishart DS. 2016. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis.
450 Current Protocols in Bioinformatics. 55(14).

451

452

453 (Kouassi Nzoughet JJ et al. 2015)

454 FIGURE CAPTIONS

455

456 Figure 1: Image of the 3D PCA score plot generated in LiveID using 10 PCA dimensions generated from
457 the training set of 106 spectra (50 control and 56 treated) across a mass range of 600-1000 m/z with a
458 binning parameter of 0.1 Da.

459 Figure 2: (a) Loadings plot PCA/LDA model (generated in LiveIDTM) showing the m/z features
460 responsible for the discrimination in the first component in the region between 600-900 m/z. (b) Loadings
461 S-Plot (generated using Progenesis QI and EZInfo 3.0.0.0) showing the significant features (m/z)
462 responsible to the discrimination between treated (upper right quadrant) and control (lower left quadrant)
463 populations. Red circles highlight the 2 example common ions seen in the Heat map representation and
464 compound abundance plots of the data set.

465 Figure 3: Hierarchal cluster analysis heat map representation (generated using MetaboAnalyst 3.0
466 software) of the features responsible for the discrimination between the control and treated pig populations
467 created from the top 50 most statistically relevant (ANOVA p-value ≤ 0.05 max fold change ≥ 2 and
468 minimum CV ≥ 30) features (in the region of 600-1200 m/z). The degree of red shading signifies up-
469 regulation whilst blue shading indicates down-regulation at the individual feature level.

470